The role of guanfacine as a therapeutic agent to address stress-related pathophysiology in cocaine-dependent individuals

Advances in Pharmacology

Volumn 69, Issue , 2014, Pages 217-265

  Fox, Helen ^a   Sinha, Rajita ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alpha 2 agonists; Anxiety; Cocaine dependence; Guanfacine; Stress

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANXIOLYTIC AGENT; COCAINE; GUANFACINE;

ANXIETY; ARTICLE; BRAIN DYSFUNCTION; BRAIN FUNCTION; COCAINE DEPENDENCE; COGNITION; COMPULSION; DRUG SEEKING BEHAVIOR; HUMAN; MAINTENANCE THERAPY; MOOD DISORDER; NONHUMAN; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; RELAPSE; STRESS; SUBSTANCE ABUSE; WITHDRAWAL SYNDROME; ALPHA-2 AGONISTS; ANIMAL; MENTAL STRESS; PSYCHOLOGICAL ASPECT; REVIEW; TREATMENT OUTCOME;

ALPHA-2 AGONISTS; ANXIETY; COCAINE DEPENDENCE; GUANFACINE; STRESS;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ANIMALS; COCAINE-RELATED DISORDERS; GUANFACINE; HUMANS; STRESS, PSYCHOLOGICAL; TREATMENT OUTCOME;

EID: 84893182821     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-420118-7.00006-8     Document Type: Chapter

References (310)

1. Ahmadi J., Kampman K., Dackis C. Outcome predictors in cocaine dependence treatment trials. The American Journal on Addictions 2006, 15(6):434-439. [Research Support, N.I.H., Extramural]. 10.1080/10550490600998476.
2. Ahmadi J., Kampman K.M., Oslin D.M., Pettinati H.M., Dackis C., Sparkman T. Predictors of treatment outcome in outpatient cocaine and alcohol dependence treatment. The American Journal on Addictions 2009, 18(1):81-86. [Randomized Controlled Trial Research Support, N.I.H., Extramural]. 10.1080/10550490802545174.
3. Albein-Urios N., Verdejo-Roman J., Asensio S., Soriano-Mas C., Martinez-Gonzalez J.M., Verdejo-Garcia A. Re-appraisal of negative emotions in cocaine dependence: Dysfunctional corticolimbic activation and connectivity. Addiction Biology 2012, 10.1111/j.1369-1600.2012.00497.x.
4. Amato L., Minozzi S., Pani P.P., Solimini R., Vecchi S., Zuccaro P., et al. Dopamine agonists for the treatment of cocaine dependence. Cochrane Database of Systematic Reviews 2011, (12):CD003352. [Meta-Analysis Review]. 10.1002/14651858.CD003352.pub3.
5. Ambrose-Lanci L.M., Sterling R.C., Van Bockstaele E.J. Cocaine withdrawal-induced anxiety in females: Impact of circulating estrogen and potential use of delta-opioid receptor agonists for treatment. Journal of Neuroscience Research 2010, 88(4):816-824. [Research Support, N.I.H., Extramural]. 10.1002/jnr.22259.
6. Anderson S.M., Pierce R.C. Cocaine-induced alterations in dopamine receptor signaling: Implications for reinforcement and reinstatement. Pharmacology & Therapeutics 2005, 106(3):389-403. [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S. Review]. 10.1016/j.pharmthera.2004.12.004.
7. Ansell E.B., Rando K., Tuit K., Guarnaccia J., Sinha R. Cumulative adversity and smaller gray matter volume in medial prefrontal, anterior cingulate, and insula regions. Biological Psychiatry 2012, 72(1):57-64. [Research Support, N.I.H., Extramural]. 10.1016/j.biopsych.2011.11.022.
8. Arnsten A.F. Catecholamine and second messenger influences on prefrontal cortical networks of "representational knowledge": A rational bridge between genetics and the symptoms of mental illness. Cerebral Cortex 2007, 17(Suppl. 1):i6-i15. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review]. 10.1093/cercor/bhm033.
9. Arnsten A.F. Ameliorating prefrontal cortical dysfunction in mental illness: Inhibition of phosphotidyl inositol-protein kinase C signaling. Psychopharmacology 2009, 202(1-3):445-455. [Research Support, N.I.H., Extramural Review]. 10.1007/s00213-008-1274-9.
10. Arnsten A.F. Catecholamine influences on dorsolateral prefrontal cortical networks. Biological Psychiatry 2011, 69(12):e89-e99. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review]. 10.1016/j.biopsych.2011.01.027.
11. Arnsten A.F. Prefrontal cortical network connections: Key site of vulnerability in stress and schizophrenia. International Journal of Developmental Neuroscience 2011, 29(3):215-223. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review]. 10.1016/j.ijdevneu.2011.02.006.
12. Arnsten A.F., Cai J.X., Goldman-Rakic P.S. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: Evidence for alpha-2 receptor subtypes. The Journal of Neuroscience 1988, 8(11):4287-4298. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
13. Arnsten A.F., Jin L.E. Guanfacine for the treatment of cognitive disorders: A century of discoveries at Yale. Yale Journal of Biology and Medicine 2012, 85(1):45-58. [Historical Article Review].
14. Arnsten A.F., Li B.M. Neurobiology of executive functions: Catecholamine influences on prefrontal cortical functions. Biological Psychiatry 2005, 57(11):1377-1384. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review]. 10.1016/j.biopsych.2004.08.019.
15. Arnsten A.F., Pliszka S.R. Catecholamine influences on prefrontal cortical function: Relevance to treatment of attention deficit/hyperactivity disorder and related disorders. Pharmacology, Biochemistry and Behavior 2011, 99(2):211-216. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review]. 10.1016/j.pbb.2011.01.020.
16. Arnsten A.F., Steere J.C., Hunt R.D. The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder. Archives of General Psychiatry 1996, 53(5):448-455. [Research Support, U.S. Gov't, P.H.S. Review].
17. Arnsten A.F., Steere J.C., Jentsch D.J., Li B.M. Noradrenergic influences on prefrontal cortical cognitive function: Opposing actions at postjunctional alpha 1 versus alpha 2-adrenergic receptors. Advances in Pharmacology 1998, 42:764-767. [Research Support, U.S. Gov't, P.H.S.].
18. Aron A.R. The neural basis of inhibition in cognitive control. The Neuroscientist 2007, 13(3):214-228. [Review]. 10.1177/1073858407299288.
19. Aston-Jones S., Aston-Jones G., Koob G.F. Cocaine antagonizes anxiolytic effects of ethanol. Psychopharmacology 1984, 84(1):28-31. [Research Support, U.S. Gov't, P.H.S.].
20. Aston-Jones G., Kalivas P.W. Brain norepinephrine rediscovered in addiction research. Biological Psychiatry 2008, 63(11):1005-1006. [Comment]. 10.1016/j.biopsych.2008.03.016.
21. Avery R.A., Franowicz J.S., Studholme C., van Dyck C.H., Arnsten A.F. The alpha-2A-adrenoceptor agonist, guanfacine, increases regional cerebral blood flow in dorsolateral prefrontal cortex of monkeys performing a spatial working memory task. Neuropsychopharmacology 2000, 23(3):240-249. 10.1016/S0893-133X(00)00111-1.
22. Back S.E., Brady K.T., Jackson J.L., Salstrom S., Zinzow H. Gender differences in stress reactivity among cocaine-dependent individuals. Psychopharmacology 2005, 180(1):169-176. 10.1007/s00213-004-2129-7.
23. Balldin J., Berggren U., Eriksson E., Lindstedt G., Sundkler A. Guanfacine as an alpha-2-agonist inducer of growth hormone secretion-a comparison with clonidine. Psychoneuroendocrinology 1993, 18(1):45-55. [Clinical Trial Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't].
24. Bardo M.T. Neuropharmacological mechanisms of drug reward: Beyond dopamine in the nucleus accumbens. Critical Reviews in Neurobiology 1998, 12(1-2):37-67.
25. Barrowclough C., Haddock G., Tarrier N., Lewis S.W., Moring J., O'Brien R., et al. Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. The American Journal of Psychiatry 2001, 158(10):1706-1713. [Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't].
26. Batki S.L., Washburn A.M., Delucchi K., Jones R.T. A controlled trial of fluoxetine in crack cocaine dependence. Drug and Alcohol Dependence 1996, 41(2):137-142. [Clinical Trial Randomized Controlled Trial Research Support, U.S. Gov't, P.H.S.].
27. Baumann M.H., Milchanowski A.B., Rothman R.B. Evidence for alterations in alpha2-adrenergic receptor sensitivity in rats exposed to repeated cocaine administration. Neuroscience 2004, 125(3):683-690. 10.1016/j.neuroscience.2004.02.013.
28. Baumeister R.F., Stillwell A.M., Heatherton T.F. Guilt: An interpersonal approach. Psychological Bulletin 1994, 115(2):243-267. [Research Support, Non-U.S. Gov't Review].
29. Bearn J., Gossop M., Strang J. Randomised double-blind comparison of lofexidine and methadone in the in-patient treatment of opiate withdrawal. Drug and Alcohol Dependence 1996, 43(1-2):87-91. [Clinical Trial Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't].
30. Becker J.B., Hu M. Sex differences in drug abuse. Frontiers in Neuroendocrinology 2008, 29(1):36-47. [Research Support, N.I.H., Extramural Review]. 10.1016/j.yfrne.2007.07.003.
31. Bergquist K.L., Fox H.C., Sinha R. Self-reports of interoceptive responses during stress and drug cue-related experiences in cocaine- and alcohol-dependent individuals. Experimental and Clinical Psychopharmacology 2010, 18(3):229-237. [Research Support, N.I.H., Extramural]. 10.1037/a0019451.
32. Beveridge T.J., Smith H.R., Nader M.A., Porrino L.J. Effects of chronic cocaine self-administration on norepinephrine transporters in the nonhuman primate brain. Psychopharmacology 2005, 180(4):781-788. [Comparative Study Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.]. 10.1007/s00213-005-2162-1.
33. Biederman J., Melmed R.D., Patel A., McBurnett K., Donahue J., Lyne A. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectrums 2008, 13(12):1047-1055. [Clinical Trial Research Support, Non-U.S. Gov't].
34. Birnbaum S.G., Podell D.M., Arnsten A.F. Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacology, Biochemistry and Behavior 2000, 67(3):397-403. [Research Support, U.S. Gov't, P.H.S.].
35. Blanc G., Trovero F., Vezina P., Herve D., Godeheu A.M., Glowinski J., et al. Blockade of prefronto-cortical alpha 1-adrenergic receptors prevents locomotor hyperactivity induced by subcortical D-amphetamine injection. The European Journal of Neuroscience 1994, 6(3):293-298. [Research Support, Non-U.S. Gov't].
36. Blanchard D.C. Stress-related psychopathology as a vulnerability factor in drug taking: The role of sex. Drug addiction research and the health of women 1998, 151-164. National Institute on Drug Abuse, NIH, Bethesda. C.L. Weatherington, A.B. Roman (Eds.).
37. Blume A.W., Marlatt G.A. The role of executive cognitive functions in changing substance use: What we know and what we need to know. Annals of Behavioral Medicine 2009, 37(2):117-125. [Review]. 10.1007/s12160-009-9093-8.
38. Blume A.W., Schmaling K.B., Marlatt G.A. Memory, executive cognitive function, and readiness to change drinking behavior. Addictive Behaviors 2005, 30(2):301-314. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. 10.1016/j.addbeh.2004.05.019.
39. Bossert J.M., Ghitza U.E., Lu L., Epstein D.H., Shaham Y. Neurobiology of relapse to heroin and cocaine seeking: An update and clinical implications. European Journal of Pharmacology 2005, 526(1-3):36-50. [Review]. 10.1016/j.ejphar.2005.09.030.
40. Boynton L., Bentley J., Strachan E., Barbato A., Raskind M. Preliminary findings concerning the use of prazosin for the treatment of posttraumatic nightmares in a refugee population. Journal of Psychiatric Practice 2009, 15(6):454-459. [Case Reports Clinical Trial]. 10.1097/01.pra.0000364287.63210.92.
41. Brady K.T., Back S.E., Waldrop A.E., McRae A.L., Anton R.F., Upadhyaya H.P., et al. Cold pressor task reactivity: Predictors of alcohol use among alcohol-dependent individuals with and without comorbid posttraumatic stress disorder. Alcoholism, Clinical and Experimental Research 2006, 30(6):938-946. [Research Support, N.I.H., Extramural]. 10.1111/j.1530-0277.2006.00097.x.
42. Brady K.T., Gray K.M., Tolliver B.K. Cognitive enhancers in the treatment of substance use disorders: Clinical evidence. Pharmacology, Biochemistry and Behavior 2011, 99(2):285-294. [Review]. 10.1016/j.pbb.2011.04.017.
43. Brady K.T., Grice D.E., Dustan L., Randall C. Gender differences in substance use disorders. The American Journal of Psychiatry 1993, 150(11):1707-1711.
44. Brebner K., Childress A.R., Roberts D.C. A potential role for GABA(B) agonists in the treatment of psychostimulant addiction. Alcohol and Alcoholism 2002, 37(5):478-484. [Review].
45. Brennan A.R., Arnsten A.F. Neuronal mechanisms underlying attention deficit hyperactivity disorder: The influence of arousal on prefrontal cortical function. Annals of the New York Academy of Sciences 2008, 1129:236-245. [Research Support, N.I.H., Extramural Review]. 10.1196/annals.1417.007.
46. Brunette M.F., Drake R.E., Woods M., Hartnett T. A comparison of long-term and short-term residential treatment programs for dual diagnosis patients. Psychiatric Services 2001, 52(4):526-528. [Comparative Study Evaluation Studies Research Support, U.S. Gov't, P.H.S.].
47. Budney A.J., Higgins S.T., Hughes J.R., Bickel W.K. Nicotine and caffeine use in cocaine-dependent individuals. Journal of Substance Abuse 1993, 5(2):117-130. [Research Support, U.S. Gov't, P.H.S.].
48. Buffalari D.M., Baldwin C.K., See R.E. Treatment of cocaine withdrawal anxiety with guanfacine: Relationships to cocaine intake and reinstatement of cocaine seeking in rats. Psychopharmacology 2012, 223(2):179-190. [Research Support, N.I.H., Extramural]. 10.1007/s00213-012-2705-1.
49. Bullers S. An exploratory study of gender and changes in alcohol consumption: A qualitative approach. Sociation Today 2012, 10(1).
50. Carelli R.M., West E.A. When a good taste turns bad: Neural mechanisms underlying the emergence of negative affect and associated natural reward devaluation by cocaine. Neuropharmacology 2013, 10.1016/j.neuropharm.2013.04.025.
51. Carroll M.E., Lac S.T., Asencio M., Kragh R. Intravenous cocaine self-administration in rats is reduced by dietary L-tryptophan. Psychopharmacology 1990, 100(3):293-300. [Research Support, U.S. Gov't, P.H.S.].
52. Castells X., Kosten T.R., Capella D., Vidal X., Colom J., Casas M. Efficacy of opiate maintenance therapy and adjunctive interventions for opioid dependence with comorbid cocaine use disorders: A systematic review and meta-analysis of controlled clinical trials. The American Journal of Drug and Alcohol Abuse 2009, 35(5):339-349. [Meta-Analysis Research Support, Non-U.S. Gov't]. 10.1080/00952990903108215.
53. Chaplin T.M., Hong K., Bergquist K., Sinha R. Gender differences in response to emotional stress: An assessment across subjective, behavioral, and physiological domains and relations to alcohol craving. Alcoholism, Clinical and Experimental Research 2008, 32(7):1242-1250. ACER679 [pii]. 10.1111/j.1530-0277.2008.00679.x.
54. Chaplin T.M., Hong K., Fox H.C., Siedlarz K.M., Bergquist K., Sinha R. Behavioral arousal in response to stress and drug cue in alcohol and cocaine addicted individuals versus healthy controls. Human Psychopharmacology 2010, 25(5):368-376. [Research Support, N.I.H., Extramural]. 10.1002/hup.1127.
55. Chappell P.B., Riddle M.A., Scahill L., Lynch K.A., Schultz R., Arnsten A., et al. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: Preliminary clinical experience. Journal of the American Academy of Child and Adolescent Psychiatry 1995, 34(9):1140-1146. [Research Support, U.S. Gov't, P.H.S.]. 10.1097/00004583-199509000-00010.
56. Colamussi L., Bovbjerg D.H., Erblich J. Stress- and cue-induced cigarette craving: Effects of a family history of smoking. Drug and Alcohol Dependence 2007, 88(2-3):251-258. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 10.1016/j.drugalcdep.2006.11.006.
57. Connor D.F., Grasso D.J., Slivinsky M.D., Pearson G.S., Banga A. An open-label study of guanfacine extended release for traumatic stress related symptoms in children and adolescents. Journal of Child and Adolescent Psychopharmacology 2013, 23(4):244-251. [Research Support, Non-U.S. Gov't]. 10.1089/cap.2012.0119.
58. Conway K.P., Compton W., Stinson F.S., Grant B.F. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the national epidemiologic survey on alcohol and related conditions. The Journal of Clinical Psychiatry 2006, 67(2):247-257. [Comparative Study Research Support, N.I.H., Extramural].
59. Covey L.S., Glassman A.H. A meta-analysis of double-blind placebo-controlled trials of clonidine for smoking cessation. British Journal of Addiction 1991, 86(8):991-998. [Clinical Trial Meta-Analysis].
60. Covi L., Hess J.M., Kreiter N.A., Haertzen C.A. Effects of combined fluoxetine and counseling in the outpatient treatment of cocaine abusers. The American Journal of Drug and Alcohol Abuse 1995, 21(3):327-344. [Clinical Trial Comparative Study Randomized Controlled Trial]. 10.3109/00952999509002701.
61. Craske M.G. Origins of phobias and anxiety disorders: Why women more than men? 2003, Elsevier, Oxford.
62. Dackis C.A., O'Brien C.P. Cocaine dependence: A disease of the brain's reward centers. Journal of Substance Abuse Treatment 2001, 21(3):111-117. [Review].
63. De Jong I.E.M., De Kloet E.R. Glucocorticoids and vulnerability to psychostimulant drugs: Toward substrate and mechanism. Annals of the New York Academy of Sciences 2004, 1018:192-198.
64. de Jong I.E., Steenbergen P.J., de Kloet E.R. Behavioral sensitization to cocaine: Cooperation between glucocorticoids and epinephrine. Psychopharmacology 2009, 204(4):693-703. [Research Support, Non-U.S. Gov't]. 10.1007/s00213-009-1498-3.
65. de Wit H., Richards J.B. Dual determinants of drug use in humans: Reward and impulsivity. Nebraska Symposium on Motivation 2004, 50:19-55. [Research Support, U.S. Gov't, P.H.S. Review].
66. Degenhardt L., Chiu W.T., Sampson N., Kessler R.C., Anthony J.C., Angermeyer M., et al. Toward a global view of alcohol, tobacco, cannabis, and cocaine use: Findings from the WHO World Mental Health Surveys. PLoS Medicine 2008, 5(7):e141. [Comparative Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 10.1371/journal.pmed.0050141.
67. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proceedings of the National Academy of Sciences 1988, 85(14):5274-5278.
68. Di Ciano P., Everitt B.J. The GABA(B) receptor agonist baclofen attenuates cocaine- and heroin-seeking behavior by rats. Neuropsychopharmacology 2003, 28(3):510-518. [Research Support, Non-U.S. Gov't]. 10.1038/sj.npp.1300088.
69. Diana M. The dopamine hypothesis of drug addiction and its potential therapeutic value. Front Psychiatry 2011, 2:64. 10.3389/fpsyt.2011.00064.
70. Drake R.E., Yovetich N.A., Bebout R.R., Harris M., McHugo G.J. Integrated treatment for dually diagnosed homeless adults. The Journal of Nervous and Mental Disease 1997, 185(5):298-305. [Clinical Trial Comparative Study Controlled Clinical Trial Research Support, U.S. Gov't, P.H.S.].
71. Dunn A.J., Berridge C.W. Physiological and behavioral responses to corticotropin-releasing factor administration: Is CRF a mediator of anxiety or stress responses?. Brain Research. Brain Research Reviews 1990, 15(2):71-100. [Research Support, U.S. Gov't, P.H.S. Review].
72. Dunn A.J., Swiergiel A.H. Effects of acute and chronic stressors and CRF in rat and mouse tests for depression. Annals of the New York Academy of Sciences 2008, 1148:118-126. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 10.1196/annals.1410.022.
73. Dunn A.J., Swiergiel A.H. The role of corticotropin-releasing factor and noradrenaline in stress-related responses, and the inter-relationships between the two systems. European Journal of Pharmacology 2008, 583(2-3):186-193. [Research Support, N.I.H., Extramural Review]. 10.1016/j.ejphar.2007.11.069.
74. Dunn A.J., Swiergiel A.H., Palamarchouk V. Brain circuits involved in corticotropin-releasing factor-norepinephrine interactions during stress. Annals of the New York Academy of Sciences 2004, 1018:25-34. [Review]. 10.1196/annals.1296.003.
75. Durell T.M., Adler L.A., Williams D.W., Deldar A., McGough J.J., Glaser P.E., et al. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: A randomized, double-blind, placebo-controlled clinical trial. Journal of Clinical Psychopharmacology 2013, 33(1):45-54. [Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't]. 10.1097/JCP.0b013e31827d8a23.
76. Eisenberg N., Fabes R.A., Schaller M., Miller P., Carlo G., Poulin R., et al. Personality and socialization correlates of vicarious emotional responding. Journal of Personality and Social Psychology 1991, 61(3):459-470. [Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.].
77. El Hage C., Rappeneau V., Etievant A., Morel A.L., Scarna H., Zimmer L., et al. Enhanced anxiety observed in cocaine withdrawn rats is associated with altered reactivity of the dorsomedial prefrontal cortex. PLoS One 2012, 7(8):e43535. [Research Support, Non-U.S. Gov't]. 10.1371/journal.pone.0043535.
78. Epstein D.H., Marrone G.F., Heishman S.J., Schmittner J., Preston K.L. Tobacco, cocaine, and heroin: Craving and use during daily life. Addictive Behaviors 2010, 35(4):318-324. [Research Support, N.I.H., Intramural]. 10.1016/j.addbeh.2009.11.003.
79. Erb S. Evaluation of the relationship between anxiety during withdrawal and stress-induced reinstatement of cocaine seeking. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2010, 34(5):798-807. [Review]. 10.1016/j.pnpbp.2009.11.025.
80. Erb S., Hitchcott P.K., Rajabi H., Mueller D., Shaham Y., Stewart J. Alpha-2 adrenergic receptor agonists block stress-induced reinstatement of cocaine seeking. Neuropsychopharmacology 2000, 23(2):138-150. [Research Support, Non-U.S. Gov't]. 10.1016/S0893-133X(99)00158-X.
81. Erb S., Shaham Y., Stewart J. The role of corticotropin-releasing factor and corticosterone in stress- and cocaine-induced relapse to cocaine seeking in rats. The Journal of Neuroscience 1998, 18(14):5529-5536. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
82. Ernst M., Zametkin A.J., Matochik J.A., Jons P.H., Cohen R.M. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study. The Journal of Neuroscience 1998, 18(15):5901-5907.
83. Everitt B.J., Dickinson A., Robbins T.W. The neuropsychological basis of addictive behaviour. Brain Research. Brain Research Reviews 2001, 36(2-3):129-138. [Research Support, Non-U.S. Gov't Review].
84. Everitt B.J., Robbins T.W. Neural systems of reinforcement for drug addiction: From actions to habits to compulsion. Nature Neuroscience 2005, 8(11):1481-1489. [Research Support, Non-U.S. Gov't Review]. 10.1038/nn1579.
85. Everitt B.J., Wolf M.E. Psychomotor stimulant addiction: A neural systems perspective. The Journal of Neuroscience 2002, 22(9):3312-3320. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review], 20026356.
86. Fattore L., Altea S., Fratta W. Sex differences in drug addiction: A review of animal and human studies. Women's Health (London, England) 2008, 4:51-65. [Review]. 10.2217/17455057.4.1.51.
87. Feltenstein M.W., See R.E. Potentiation of cue-induced reinstatement of cocaine-seeking in rats by the anxiogenic drug yohimbine. Behavioural Brain Research 2006, 174(1):1-8. [Comparative Study Research Support, N.I.H., Extramural]. 10.1016/j.bbr.2006.06.039.
88. Fishbein D.H., Eldreth D.L., Hyde C., Matochik J.A., London E.D., Contoreggi C., et al. Risky decision making and the anterior cingulate cortex in abstinent drug abusers and nonusers. Brain Research. Cognitive Brain Research 2005, 23(1):119-136. [Clinical Trial Research Support, U.S. Gov't, Non-P.H.S.]. 10.1016/j.cogbrainres.2004.12.010.
89. Fitzgerald L.W., Burn T.C., Brown B.S., Patterson J.P., Corjay M.H., Valentine P.A., et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Molecular Pharmacology 2000, 57(1):75-81.
90. Foote S.L., Bloom F.E., Aston-Jones G. Nucleus locus ceruleus: New evidence of anatomical and physiological specificity. Physiological Reviews 1983, 63(3):844-914. [Research Support, U.S. Gov't, P.H.S. Review].
91. Fox H.C., Anderson G.M., Tuit K., Hansen J., Kimmerling A., Siedlarz K.M., et al. Prazosin effects on stress- and cue-induced craving and stress response in alcohol-dependent individuals: Preliminary findings. Alcoholism, Clinical and Experimental Research 2012, 36(2):351-360. [Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 10.1111/j.1530-0277.2011.01628.x.
92. Fox H.C., Bergquist K.L., Hong K.I., Sinha R. Stress-induced and alcohol cue-induced craving in recently abstinent alcohol-dependent individuals. Alcoholism, Clinical and Experimental Research 2007, 31(3):395-403. [Research Support, N.I.H., Extramural]. 10.1111/j.1530-0277.2006.00320.x.
93. Fox H.C., Bergquist K.L., Peihua G., Rajita S. Interactive effects of cumulative stress and impulsivity on alcohol consumption. Alcoholism, Clinical and Experimental Research 2010, 34(8):1376-1385. [Comparative Study Research Support, N.I.H., Extramural]. 10.1111/j.1530-0277.2010.01221.x.
94. Fox H.C., Garcia M., Kemp K., Milivojevic V., Kreek M.J., Sinha R. Gender differences in cardiovascular and corticoadrenal response to stress and drug cues in cocaine dependent individuals. Psychopharmacology 2006, 185(3):348-357. [Research Support, N.I.H., Extramural]. 10.1007/s00213-005-0303-1.
95. Fox H.C., Hong K.A., Paliwal P., Morgan P.T., Sinha R. Altered levels of sex and stress steroid hormones assessed daily over a 28-day cycle in early abstinent cocaine-dependent females. Psychopharmacology 2008, 195(4):527-536. [Research Support, N.I.H., Extramural]. 10.1007/s00213-007-0936-3.
96. Fox H.C., Hong K.I., Siedlarz K.M., Bergquist K., Anderson G., Kreek M.J., et al. Sex-specific dissociations in autonomic and HPA responses to stress and cues in alcohol-dependent patients with cocaine abuse. Alcohol and Alcoholism 2009, 44(6):575-585. [Comparative Study Research Support, N.I.H., Extramural]. 10.1093/alcalc/agp060.
97. Fox H.C., Hong K.I., Siedlarz K., Sinha R. Enhanced sensitivity to stress and drug/alcohol craving in abstinent cocaine-dependent individuals compared to social drinkers. Neuropsychopharmacology 2008, 33(4):796-805. [Comparative Study Research Support, N.I.H., Extramural]. 10.1038/sj.npp.1301470.
98. Fox H.C., Jackson E.D., Sinha R. Elevated cortisol and learning and memory deficits in cocaine dependent individuals: Relationship to relapse outcomes. Psychoneuroendocrinology 2009, 34(8):1198-1207. [Research Support, N.I.H., Extramural]. 10.1016/j.psyneuen.2009.03.007.
99. Fox H.C., Morgan P.T., Sinha R. Sex differences in guanfacine effects on drug craving and stress arousal in cocaine dependent individuals. Neuropsychopharmacology 2013.
100. Fox H.C., Seo D., Tuit K., Hansen J., Kimmerling A., Morgan P.T., et al. Guanfacine effects on stress, drug craving and prefrontal activation in cocaine dependent individuals: Preliminary findings. Journal of Psychopharmacology 2012, 26(7):958-972. [Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 10.1177/0269881111430746.
101. Fox H.C., Sinha R. Sex differences in drug-related stress-system changes: Implications for treatment in substance-abusing women. Harvard Review of Psychiatry 2009, 17(2):103-119. 10.1080/10673220902899680.
102. Fox H.C., Talih M., Malison R., Anderson G.M., Kreek M.J., Sinha R. Frequency of recent cocaine and alcohol use affects drug craving and associated responses to stress and drug-related cues. Psychoneuroendocrinology 2005, 30(9):880-891. [Clinical Trial Comparative Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.]. 10.1016/j.psyneuen.2005.05.002.
103. Fraleigh L.A., Hendratta V.D., Ford J.D., Connor D.F. Prazosin for the treatment of posttraumatic stress disorder-related nightmares in an adolescent male. Journal of Child and Adolescent Psychopharmacology 2009, 19(4):475-476. [Case Reports Letter]. 10.1089/cap.2009.0002.
104. Franklin T.R., Acton P.D., Maldjian J.A., Gray J.D., Croft J.R., Dackis C.A., et al. Decreased gray matter concentration in the insular, orbitofrontal, cingulate, and temporal cortices of cocaine patients. Biological Psychiatry 2002, 51(2):134-142. [Research Support, U.S. Gov't, P.H.S.].
105. Franowicz J.S., Arnsten A.F. The alpha-2a noradrenergic agonist, guanfacine, improves delayed response performance in young adult rhesus monkeys. Psychopharmacology 1998, 136(1):8-14.
106. Franowicz J.S., Arnsten A.F. Actions of alpha-2 noradrenergic agonists on spatial working memory and blood pressure in rhesus monkeys appear to be mediated by the same receptor subtype. Psychopharmacology 2002, 162(3):304-312. [Research Support, U.S. Gov't, P.H.S.]. 10.1007/s00213-002-1110-6.
107. Frye C.A., Petralia S.M., Rhodes M.E. Estrous cycle and sex differences in performance on anxiety tasks coincide with increases in hippocampal progesterone and 3alpha,5alpha-THP. Pharmacology, Biochemistry and Behavior 2000, 67(3):587-596. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.].
108. Gabriel A., Violato C. Adjunctive atomoxetine to SSRIs or SNRIs in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety (GA): An open-label study. Attention Deficit and Hyperactivity Disorders 2011, 3(4):319-326. [Clinical Trial]. 10.1007/s12402-011-0063-1.
109. Gallagher M., McMahan R.W., Schoenbaum G. Orbitofrontal cortex and representation of incentive value in associative learning. The Journal of Neuroscience 1999, 19(15):6610-6614. [Research Support, U.S. Gov't, P.H.S.].
110. Gamo N.J., Arnsten A.F. Molecular modulation of prefrontal cortex: Rational development of treatments for psychiatric disorders. Behavioral Neuroscience 2011, 125(3):282-296. [Review]. 10.1037/a0023165.
111. Garavan H., Hester R. The role of cognitive control in cocaine dependence. Neuropsychology Review 2007, 17(3):337-345. [Review]. 10.1007/s11065-007-9034-x.
112. Gish E.C., Miller J.L., Honey B.L., Johnson P.N. Lofexidine, an {alpha}2-receptor agonist for opioid detoxification. Annals of Pharmacotherapy 2010, 44(2):343-351. [Review]. 10.1345/aph.1M347.
113. Glassman A.H., Covey L.S., Dalack G.W., Stetner F., Rivelli S.K., Fleiss J., et al. Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. Clinical Pharmacology and Therapeutics 1993, 54(6):670-679. [Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
114. Glassman A.H., Jackson W.K., Walsh B.T., Roose S.P., Rosenfeld B. Cigarette craving, smoking withdrawal, and clonidine. Science 1984, 226(4676):864-866. [Clinical Trial].
115. Glassman A.H., Stetner F., Walsh B.T., Raizman P.S., Fleiss J.L., Cooper T.B., et al. Heavy smokers, smoking cessation, and clonidine. Results of a double-blind, randomized trial. JAMA 1988, 259(19):2863-2866. [Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't].
116. Godley S.H., Godley M.D., Pratt A., Wallace J.L. Case management services for adolescent substance abusers: A program description. Journal of Substance Abuse Treatment 1994, 11(4):309-317. [Research Support, Non-U.S. Gov't Review].
117. Goeders N.E. Stress and cocaine addiction. The Journal of Pharmacology and Experimental Therapeutics 2002, 301(3):785-789. [Research Support, U.S. Gov't, P.H.S. Review].
118. Goldstein R.Z., Alia-Klein N., Tomasi D., Carrillo J.H., Maloney T., Woicik P.A., et al. Anterior cingulate cortex hypoactivations to an emotionally salient task in cocaine addiction. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(23):9453-9458. [Research Support, N.I.H., Extramural]. 10.1073/pnas.0900491106.
119. Goldstein R.Z., Volkow N.D. Drug addiction and its underlying neurobiological basis: Neuroimaging evidence for the involvement of the frontal cortex. The American Journal of Psychiatry 2002, 159(10):1642-1652. [Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S. Review].
120. Gonzales G., Sevarino K., Sofuoglu M., Poling J., Oliveto A., Gonsai K., et al. Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: Results of a randomized pilot study. Addiction 2003, 98:1625-1632.
121. Gowing L., Farrell M., Ali R., White J.M. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database of Systematic Reviews 2009, (2):CD002024. [Meta-Analysis Review]. 10.1002/14651858.CD002024.pub3.
122. Grabowski J., Shearer J., Merrill J., Negus S.S. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addictive Behaviors 2004, 29(7):1439-1464. [Research Support, U.S. Gov't, P.H.S. Review]. 10.1016/j.addbeh.2004.06.018.
123. Grella C.E., Anglin M.D., Wugalter S.E. Cocaine and crack use and HIV risk behaviors among high-risk methadone maintenance clients. Drug and Alcohol Dependence 1995, 37(1):15-21. [Research Support, U.S. Gov't, P.H.S.].
124. Haber S.N., Fudge J.L., McFarland N.R. Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum. The Journal of Neuroscience 2000, 20(6):2369-2382. [Research Support, U.S. Gov't, P.H.S.].
125. Haney M., Hart C.L., Vosburg S.K., Comer S.D., Reed S.C., Cooper Z.D., et al. Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse. Psychopharmacology 2010, 211(2):233-244. [Controlled Clinical Trial Research Support, N.I.H., Extramural]. 10.1007/s00213-010-1888-6.
126. Harris G.C., Aston-Jones G. Beta-adrenergic antagonists attenuate withdrawal anxiety in cocaine- and morphine-dependent rats. Psychopharmacology 1993, 113(1):131-136. [Research Support, U.S. Gov't, P.H.S.].
127. Heinsbroek R.P., van Haaren F., Feenstra M.G., van Galen H., Boer G., van de Poll N.E. Sex differences in the effects of inescapable footshock on central catecholaminergic and serotonergic activity. Pharmacology, Biochemistry and Behavior 1990, 37(3):539-550.
128. Heinsbroek R.P., Van Haaren F., Van de Poll N.E., Steenbergen H.L. Sex differences in the behavioral consequences of inescapable footshocks depend on time since shock. Physiology and Behavior 1991, 49(6):1257-1263.
129. Heinzerling K.G., Swanson A.N., Kim S., Cederblom L., Moe A., Ling W., et al. Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. Drug and Alcohol Dependence 2010, 109(1-3):20-29. [Randomized Controlled Trial Research Support, N.I.H., Extramural]. 10.1016/j.drugalcdep.2009.11.023.
130. Highfield D., Yap J., Grimm J.W., Shalev U., Shaham Y. Repeated lofexidine treatment attenuates stress-induced, but not drug cues-induced reinstatement of a heroin-cocaine mixture (speedball) seeking in rats. Neuropsychopharmacology 2001, 25(3):320-331. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. 10.1016/S0893-133X(01)00227-5.
131. Horrigan J.P., Barnhill L.J. Does guanfacine trigger mania in children?. Journal of Child and Adolescent Psychopharmacology 1998, 8(2):149-150. [Case Reports Letter].
132. Hunt R.D., Arnsten A.F., Asbell M.D. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry 1995, 34(1):50-54. 10.1097/00004583-199501000-00013.
133. Hyman S.M., Paliwal P., Chaplin T.M., Mazure C.M., Rounsaville B.J., Sinha R. Severity of childhood trauma is predictive of cocaine relapse outcomes in women but not men. Drug and Alcohol Dependence 2008, 92(1-3):208-216. [Research Support, N.I.H., Extramural]. 10.1016/j.drugalcdep.2007.08.006.
134. Hyman S.M., Paliwal P., Sinha R. Childhood maltreatment, perceived stress, and stress-related coping in recently abstinent cocaine dependent adults. Psychology of Addictive Behaviors 2007, 21(2):233-238. [Research Support, N.I.H., Extramural]. 10.1037/0893-164X.21.2.233.
135. Ijff D.M., Aldenkamp A.P. Cognitive side-effects of antiepileptic drugs in children. Handbook of Clinical Neurology 2013, 111:707-718. 10.1016/B978-0-444-52891-9.00073-7.
136. Jakala P., Riekkinen M., Sirvio J., Koivisto E., Kejonen K., Vanhanen M., et al. Guanfacine, but not clonidine, improves planning and working memory performance in humans. Neuropsychopharmacology 1999, 20(5):460-470. [Clinical Trial Comparative Study Randomized Controlled Trial]. 10.1016/S0893-133X(98)00127-4.
137. Jakala P., Riekkinen M., Sirvio J., Koivisto E., Riekkinen P. Clonidine, but not guanfacine, impairs choice reaction time performance in young healthy volunteers. Neuropsychopharmacology 1999, 21(4):495-502. [Clinical Trial Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't]. 10.1016/S0893-133X(99)00048-2.
138. Jakala P., Sirvio J., Riekkinen M., Koivisto E., Kejonen K., Vanhanen M., et al. Guanfacine and clonidine, alpha 2-agonists, improve paired associates learning, but not delayed matching to sample, in humans. Neuropsychopharmacology 1999, 20(2):119-130. [Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't]. 10.1016/S0893-133X(98)00055-4.
139. Jarrott B., Louis W.J., Summers R.J. [3H]-guanfacine: A radioligand that selectively labels high affinity alpha2-adrenoceptor sites in homogenates of rat brain. British Journal of Pharmacology 1982, 75(2):401-408. [In Vitro Research Support, Non-U.S. Gov't].
140. Jastreboff A.M., Potenza M.N., Lacadie C., Hong K.A., Sherwin R.S., Sinha R. Body mass index, metabolic factors, and striatal activation during stressful and neutral-relaxing states: An FMRI study. Neuropsychopharmacology 2011, 36(3):627-637. [Research Support, N.I.H., Extramural]. 10.1038/npp.2010.194.
141. Jetmalani A.N. Tourette Syndrome. Child and adolescent psychiatry: The essentials 2010, 160-175. Wolters and Kluwer health Lippincott Williams and Wilkins, New York, Philadelphia, London. 2nd ed. K. Cheng, K.M. Myers (Eds.).
142. Ji X.H., Ji J.Z., Zhang H., Li B.M. Stimulation of alpha2-adrenoceptors suppresses excitatory synaptic transmission in the medial prefrontal cortex of rat. Neuropsychopharmacology 2008, 33(9):2263-2271. [In Vitro Research Support, Non-U.S. Gov't]. 10.1038/sj.npp.1301603.
143. Johanson C.E., Fischman M.W. The pharmacology of cocaine related to its abuse. Pharmacological Reviews 1989, 41(1):3-52.
144. Kahn A., Mumford J.P., Rogers G.A., Beckford H. Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital. Drug and Alcohol Dependence 1997, 44(1):57-61. [Clinical Trial Comparative Study Randomized Controlled Trial].
145. Kajantie E., Phillips D.I. The effects of sex and hormonal status on the physiological response to acute psychosocial stress. Psychoneuroendocrinology 2006, 31(2):151-178. [Research Support, Non-U.S. Gov't Review]. 10.1016/j.psyneuen.2005.07.002.
146. Kalivas P.W., & Duffy P. Effect of acute and daily cocaine treatment on extracellular dopamine in the nucleus accumbens. Synapse (New York, N.Y.) 1990, 5(1):48-58.
147. Kalivas P.W., Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Research. Brain Research Reviews 1991, 16(3):223-244. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review].
148. Kalivas P.W., Volkow N.D. The neural basis of addiction: A pathology of motivation and choice. The American Journal of Psychiatry 2005, 162(8):1403-1413. [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S. Review]. 10.1176/appi.ajp.162.8.1403.
149. Kampman K.M. The search for medications to treat stimulant dependence. Addiction Science & Clinical Practice 2008, 4(2):28-35.
150. Kampman K.M., Alterman A.I., Volpicelli J.R., Maany I., Muller E.S., Luce D.D., et al. Cocaine withdrawal symptoms and initial urine toxicology results predict treatment attrition in outpatient cocaine dependence treatment. Psychology of Addictive Behaviors 2001, 15(1):52-59. [Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.].
151. Kampman K.M., Dackis C., Lynch K.G., Pettinati H., Tirado C., Gariti P., et al. A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. Drug and Alcohol Dependence 2006, 85(2):129-137. [Randomized Controlled Trial Research Support, N.I.H., Extramural]. 10.1016/j.drugalcdep.2006.04.002.
152. Kampman K.M., Pettinati H., Lynch K.G., Dackis C., Sparkman T., Weigley C., et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug and Alcohol Dependence 2004, 75(3):233-240. [Comparative Study Research Support, U.S. Gov't, P.H.S.]. 10.1016/j.drugalcdep.2004.03.008.
153. Kampman K.M., Rukstalis M., Ehrman R., McGinnis D.E., Gariti P., Volpicelli J.R., et al. Open trials as a method of prioritizing medications for inclusion in controlled trials for cocaine dependence. Addictive Behaviors 1999, 24(2):287-291. [Clinical Trial Controlled Clinical Trial Research Support, U.S. Gov't, P.H.S.].
154. Kampman K.M., Volpicelli J.R., McGinnis D.E., Alterman A.I., Weinrieb R.M., D'Angelo L., et al. Reliability and validity of the Cocaine Selective Severity Assessment. Addictive Behaviors 1998, 23(4):449-461. [Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.].
155. Kampman K.M., Volpicelli J.R., Mulvaney F., Alterman A.I., Cornish J., Gariti P., et al. Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity. Drug and Alcohol Dependence 2001, 63(1):69-78. [Clinical Trial Randomized Controlled Trial Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.].
156. Kang S.Y., Kleinman P.H., Woody G.E., Millman R.B., Todd T.C., Kemp J., et al. Outcomes for cocaine abusers after once-a-week psychosocial therapy. The American Journal of Psychiatry 1991, 148(5):630-635. [Clinical Trial Comparative Study Randomized Controlled Trial Research Support, U.S. Gov't, P.H.S.].
157. Kelly M.M., Tyrka A.R., Anderson G.M., Price L.H., Carpenter L.L. Sex differences in emotional and physiological responses to the Trier Social Stress Test. Journal of Behavior Therapy and Experimental Psychiatry 2008, 39(1):87-98. [Comparative Study Research Support, Non-U.S. Gov't]. 10.1016/j.jbtep.2007.02.003.
158. Kessler R.C., Crum R.M., Warner L.A., Nelson C.B., Schulenberg J., Anthony J.C. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Archives of General Psychiatry 1997, 54(4):313-321. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
159. Kober H., Kross E.F., Mischel W., Hart C.L., Ochsner K.N. Regulation of craving by cognitive strategies in cigarette smokers. Drug and Alcohol Dependence 2010, 106(1):52-55. [Research Support, N.I.H., Extramural]. 10.1016/j.drugalcdep.2009.07.017.
160. Koob G.F. Neural mechanisms of drug reinforcement. Annals of the New York Academy of Sciences 1992, 654:171-191. [Research Support, U.S. Gov't, P.H.S. Review].
161. Koob G.F., Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 2001, 24(2):97-129.
162. Koob G.F. Neuroadaptive mechanisms of addiction: Studies on the extended amygdala. European Neuropsychopharmacology 2003, 13(6):442-452. [Research Support, U.S. Gov't, P.H.S. Review].
163. Koob G.F. Brain stress systems in the amygdala and addiction. Brain Research 2009, 1293:61-75. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review]. 10.1016/j.brainres.2009.03.038.
164. Koob G.F. New dimensions in human laboratory models of addiction. Addiction Biology 2009, 14(1):1-8. [Editorial Introductory Research Support, N.I.H., Extramural]. 10.1111/j.1369-1600.2008.00127.x.
165. Koob G.F., Caine B., Markou A., Pulvirenti L., Weiss F. Role for the mesocortical dopamine system in the motivating effects of cocaine. NIDA Research Monograph 1994, 145:1-18. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review].
166. Koob G.F., Le Moal M. Plasticity of reward neurocircuitry and the 'dark side' of drug addiction. Nature Neuroscience 2005, 8(11):1442-1444. 10.1038/nn1105-1442.
167. Koob G.F., Volkow N.D. Neurocircuitry of addiction. Neuropsychopharmacology 2010, 35(1):217-238. [Research Support, N.I.H., Extramural Review]. 10.1038/npp.2009.110.
168. Koole S.L., Jostmann N.B. Getting a grip on your feelings: Effects of action orientation and external demands on intuitive affect regulation. Journal of Personality and Social Psychology 2004, 87(6):974-990. [Research Support, Non-U.S. Gov't]. 10.1037/0022-3514.87.6.974.
169. Kosten T.R., Rounsaville B.J., Kleber H.D. A 2.5-year follow-up of cocaine use among treated opioid addicts. Have our treatments helped?. Archives of General Psychiatry 1987, 44(3):281-284. [Research Support, U.S. Gov't, P.H.S.].
170. Kuhar M.J., Ritz M.C., Boja J.W. The dopamine hypothesis of the reinforcing properties of cocaine. Trends in Neurosciences 1991, 14(7):299-302. [Review].
171. Kuhl J., Koole S.L. Workings of the will. Handbook of experimental existential psychology 2004, 411-430. Guildford Press, New York. J. Greenberg, S.L. Koole, T. Pyszczynski (Eds.).
172. Kushner M.G., Abrams K., Borchardt C. The relationship between anxiety disorders and alcohol use disorders: A review of major perspectives and findings. Clinical Psychology Review 2000, 20(2):149-171. [Research Support, U.S. Gov't, P.H.S. Review].
173. Lapiz M.D., Morilak D.A. Noradrenergic modulation of cognitive function in rat medial prefrontal cortex as measured by attentional set shifting capability. Neuroscience 2006, 137(3):1039-1049. [Research Support, N.I.H., Extramural]. 10.1016/j.neuroscience.2005.09.031.
174. Lazeron R.H., Rombouts S.A., Machielsen W.C., Scheltens P., Witter M.P., Uylings H.B., et al. Visualizing brain activation during planning: The tower of London test adapted for functional MR imaging. American Journal of Neuroradiology 2000, 21(8):1407-1414. [Research Support, Non-U.S. Gov't].
175. Le A.D., Funk D., Juzytsch W., Coen K., Navarre B.M., Cifani C., et al. Effect of prazosin and guanfacine on stress-induced reinstatement of alcohol and food seeking in rats. Psychopharmacology 2011, 218(1):89-99. [Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural]. 10.1007/s00213-011-2178-7.
176. Lee B., Tiefenbacher S., Platt D.M., Spealman R.D. Pharmacological blockade of alpha2-adrenoceptors induces reinstatement of cocaine-seeking behavior in squirrel monkeys. Neuropsychopharmacology 2004, 29(4):686-693. [Comparative Study Research Support, U.S. Gov't, P.H.S.]. 10.1038/sj.npp.1300391.
177. Lejuez C.W., Zvolensky M.J., Daughters S.B., Bornovalova M.A., Paulson A., Tull M.T., et al. Anxiety sensitivity: A unique predictor of dropout among inner-city heroin and crack/cocaine users in residential substance use treatment. Behaviour Research and Therapy 2008, 46(7):811-818. 10.1016/j.brat.2008.03.010.
178. Levy F. Pharmacological and therapeutic directions in ADHD: Specificity in the PFC. Behavioral and Brain Functions 2008, 4:12. 10.1186/1744-9081-4-12.
179. Li C.S., Kosten T.R., Sinha R. Sex differences in brain activation during stress imagery in abstinent cocaine users: A functional magnetic resonance imaging study. Biological Psychiatry 2005, 57(5):487-494. [Comparative Study Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. 10.1016/j.biopsych.2004.11.048.
180. Li C.S., Luo X., Yan P., Bergquist K., Sinha R. Altered impulse control in alcohol dependence: Neural measures of stop signal performance. Alcoholism, Clinical and Experimental Research 2009, 33(4):740-750. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 10.1111/j.1530-0277.2008.00891.x.
181. Li X., Risbrough V.B., Cates-Gatto C., Kaczanowska K., Finn M.G., Roberts A.J., et al. Comparison of the effects of the GABAB receptor positive modulator BHF177 and the GABAB receptor agonist baclofen on anxiety-like behavior, learning, and memory in mice. Neuropharmacology 2013, 70:156-167. [Research Support, N.I.H., Extramural]. 10.1016/j.neuropharm.2013.01.018.
182. Lim K.O., Choi S.J., Pomara N., Wolkin A., Rotrosen J.P. Reduced frontal white matter integrity in cocaine dependence: A controlled diffusion tensor imaging study. Biological Psychiatry 2002, 51(11):890-895. [Research Support, U.S. Gov't, Non-P.H.S.].
183. Ling W., Shoptaw S., Majewska D. Baclofen as a cocaine anti-craving medication: A preliminary clinical study. Neuropsychopharmacology 1998, 18(5):403-404. [Clinical Trial Letter Research Support, U.S. Gov't, P.H.S.]. 10.1016/S0893-133X(97)00128-0.
184. Ma C.L., Arnsten A.F., Li B.M. Locomotor hyperactivity induced by blockade of prefrontal cortical alpha2-adrenoceptors in monkeys. Biological Psychiatry 2005, 57(2):192-195. [Research Support, Non-U.S. Gov't]. 10.1016/j.biopsych.2004.11.004.
185. Mantsch J.R., Weyer A., Vranjkovic O., Beyer C.E., Baker D.A., Caretta H. Involvement of noradrenergic neurotransmission in the stress- but not cocaine-induced reinstatement of extinguished cocaine-induced conditioned place preference in mice: Role for beta-2 adrenergic receptors. Neuropsychopharmacology 2010, 35(11):2165-2178. [Comparative Study Research Support, N.I.H., Extramural]. 10.1038/npp.2010.86.
186. Mao Z.M., Arnsten A.F., Li B.M. Local infusion of an alpha-1 adrenergic agonist into the prefrontal cortex impairs spatial working memory performance in monkeys. Biological Psychiatry 1999, 46(9):1259-1265. [Research Support, Non-U.S. Gov't].
187. Marcinkiewcz C.A., Prado M.M., Isaac S.K., Marshall A., Rylkova D., Bruijnzeel A.W. Corticotropin-releasing factor within the central nucleus of the amygdala and the nucleus accumbens shell mediates the negative affective state of nicotine withdrawal in rats. Neuropsychopharmacology 2009, 34(7):1743-1752. [Research Support, N.I.H., Extramural]. 10.1038/npp.2008.231.
188. Marlatt G.A., George W.H. Relapse prevention: Introduction and overview of the model. British Journal of Addiction 1984, 79(3):261-273.
189. Marlatt G.A., Gordon J.R. Relapse prevention: Maintenance strategies in the treatment of addictive behaviors 1985, Guildford Press, New York.
190. McCance-Katz E.F., Carroll K.M., Rounsaville B.J. Gender differences in treatment-seeking cocaine abusers-implications for treatment and prognosis. The American Journal on Addictions 1999, 8(4):300-311. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
191. McDougle C.J., Black J.E., Malison R.T., Zimmermann R.C., Kosten T.R., Heninger G.R., et al. Noradrenergic dysregulation during discontinuation of cocaine use in addicts. Archives of General Psychiatry 1994, 51(9):713-719. [Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
192. McGaugh J.L. Dissociating learning and performance: Drug and hormone enhancement of memory storage. Brain Research Bulletin 1989, 23(4-5):339-345. [Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S. Review].
193. McKay J.R., Alterman A.I., Mulvaney F.D., Koppenhaver J.M. Predicting proximal factors in cocaine relapse and near miss episodes: Clinical and theoretical implications. Drug and Alcohol Dependence 1999, 56(1):67-78. [Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.].
194. McPherson M., Casswell S., Pledger M. Gender convergence in alcohol consumption and related problems: Issues and outcomes from comparisons of New Zealand survey data. Addiction 2004, 99(6):738-748. 10.1111/j.1360-0443.2004.00758.x.
195. Mereu M., Bonci A., Newman A.H., Tanda G. The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders. Psychopharmacology 2013, 229(3):415-434. [Comparative Study Research Support, Non-U.S. Gov't]. 10.1007/s00213-013-3232-4.
196. Milstein J.A., Lehmann O., Theobald D.E., Dalley J.W., Robbins T.W. Selective depletion of cortical noradrenaline by anti-dopamine beta-hydroxylase-saporin impairs attentional function and enhances the effects of guanfacine in the rat. Psychopharmacology 2007, 190(1):51-63. [Research Support, Non-U.S. Gov't]. 10.1007/s00213-006-0594-x.
197. Minzenberg M.J., Carter C.S. Modafinil: A review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008, 33(7):1477-1502. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review]. 10.1038/sj.npp.1301534.
198. Morton W.A. Cocaine and psychiatric symptoms. Primary Care Companion to the Journal of Clinical Psychiatry 1999, 1(4):109-113.
199. Mosqueda-Garcia R. Guanfacine: A second generation alpha 2-adrenergic blocker. The American Journal of the Medical Sciences 1990, 299(1):73-76. [Comparative Study Review].
200. Muller U., Clark L., Lam M.L., Moore R.M., Murphy C.L., Richmond N.K., et al. Lack of effects of guanfacine on executive and memory functions in healthy male volunteers. Psychopharmacology 2005, 182(2):205-213. [Randomized Controlled Trial Research Support, Non-U.S. Gov't]. 10.1007/s00213-005-0078-4.
201. Naifeh J.A., Tull M.T., Gratz K.L. Anxiety sensitivity, emotional avoidance, and PTSD symptom severity among crack/cocaine dependent patients in residential treatment. Cognitive Therapy and Research 2012, 36(3):247-257. 10.1007/s10608-010-9337-8.
202. Nolen-Hoeksema S., Larson J., Grayson C. Explaining the gender difference in depressive symptoms. Journal of Personality and Social Psychology 1999, 77(5):1061-1072. [Research Support, U.S. Gov't, P.H.S.].
203. O'Brien C.P. Anticraving medications for relapse prevention: A possible new class of psychoactive medications. The American Journal of Psychiatry 2005, 162(8):1423-1431. [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S. Review]. 10.1176/appi.ajp.162.8.1423.
204. O'Brien M.S., Anthony J.C. Risk of becoming cocaine dependent: Epidemiological estimates for the United States, 2000-2001. Neuropsychopharmacology 2005, 30(5):1006-1018. [Research Support, U.S. Gov't, P.H.S.]. 10.1038/sj.npp.1300681.
205. O'Leary T.A., Rohsenow D.J., Martin R., Colby S.M., Eaton C.A., Monti P.M. The relationship between anxiety levels and outcome of cocaine abuse treatment. The American Journal of Drug and Alcohol Abuse 2000, 26(2):179-194.
206. Opitz K. The effect of clonidine and related substances on voluntary ethanol consumption in rats. Drug and Alcohol Dependence 1990, 25(1):43-48. [Comparative Study].
207. Parale M.P., Kulkarni S.K. Studies with alpha 2-adrenoceptor agonists and alcohol abstinence syndrome in rats. Psychopharmacology 1986, 88(2):237-239. [Comparative Study Research Support, Non-U.S. Gov't].
208. Patkar A.A., Gopalakrishnan R., Naik P.C., Murray H.W., Vergare M.J., Marsden C.A. Changes in plasma noradrenaline and serotonin levels and craving during alcohol withdrawal. Alcohol and Alcoholism 2003, 38(3):224-231. [Research Support, Non-U.S. Gov't].
209. Patkar A.A., Mannelli P., Peindl K., Murray H.W., Meier B., Leone F.T. Changes in tobacco smoking following treatment for cocaine dependence. The American Journal of Drug and Alcohol Abuse 2006, 32(2):135-148. [Research Support, N.I.H., Extramural]. 10.1080/00952990500479209.
210. Patkar A.A., Marsden C.A., Naik P.C., Kendall D.A., Gopalakrishnan R., Vergare M.J., et al. Differences in peripheral noradrenergic function among actively drinking and abstinent alcohol-dependent individuals. The American Journal on Addictions 2004, 13(3):225-235. [Research Support, Non-U.S. Gov't]. 10.1080/10550490490459898.
211. Paulus M.P., Tapert S.F., Schuckit M.A. Neural activation patterns of methamphetamine-dependent subjects during decision making predict relapse. Archives of General Psychiatry 2005, 62(7):761-768. [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.]. 10.1001/archpsyc.62.7.761.
212. Peles E., Kreek M.J., Kellogg S., Adelson M. High methadone dose significantly reduces cocaine use in methadone maintenance treatment (MMT) patients. Journal of Addictive Diseases 2006, 25(1):43-50. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 10.1300/J069v25n01_07.
213. Peltier R., Schenk S. Effects of serotonergic manipulations on cocaine self-administration in rats. Psychopharmacology 1993, 110(4):390-394. [Comparative Study Research Support, U.S. Gov't, P.H.S.].
214. Petrides M., Milner B. Deficits on subject-ordered tasks after frontal- and temporal-lobe lesions in man. Neuropsychologia 1982, 20(3):249-262. [Research Support, Non-U.S. Gov't].
215. Piazza P.V., Le Moal M. Glucocorticoids as a biological substrate of reward: Physiological and pathophysiological implications. Brain Research. Brain Research Reviews 1997, 25(3):359-372. [Research Support, Non-U.S. Gov't Review].
216. Porrino L.J., Lyons D., Smith H.R., Daunais J.B., Nader M.A. Cocaine self-administration produces a progressive involvement of limbic, association, and sensorimotor striatal domains. The Journal of Neuroscience 2004, 24(14):3554-3562. [Research Support, U.S. Gov't, P.H.S.]. 10.1523/JNEUROSCI.5578-03.2004.
217. Quinones-Jenab V. Why are women from Venus and men from Mars when they abuse cocaine?. Brain Research 2006, 1126(1):200-203. [Research Support, N.I.H., Extramural Review]. 10.1016/j.brainres.2006.08.109.
218. Rabbitt P. Methodologies and models in the study of executive function. Methodology of frontal and executive function 1997, Psychology Press Ltd., East Sussex. P. Rabbitt (Ed.).
219. Rama P., Linnankoski I., Tanila H., Pertovaara A., Carlson S. Medetomidine, atipamezole, and guanfacine in delayed response performance of aged monkeys. Pharmacology, Biochemistry and Behavior 1996, 55(3):415-422. [Comparative Study Research Support, Non-U.S. Gov't].
220. Ramos B.P., Arnsten A.F. Adrenergic pharmacology and cognition: Focus on the prefrontal cortex. Pharmacology & Therapeutics 2007, 113(3):523-536. [Research Support, N.I.H., Extramural Review]. 10.1016/j.pharmthera.2006.11.006.
221. Ramos B.P., Stark D., Verduzco L., van Dyck C.H., Arnsten A.F. Alpha2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animals. Learning and Memory 2006, 13(6):770-776. [Comparative Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 10.1101/lm.298006.
222. Randall D.C., Shneerson J.M., Plaha K.K., File S.E. Modafinil affects mood, but not cognitive function, in healthy young volunteers. Human Psychopharmacology 2003, 18(3):163-173. [Clinical Trial Randomized Controlled Trial]. 10.1002/hup.456.
223. Raskind M.A., Peskind E.R., Hoff D.J., Hart K.L., Holmes H.A., Warren D., et al. A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biological Psychiatry 2007, 61(8):928-934. [Evaluation Studies Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.]. 10.1016/j.biopsych.2006.06.032.
224. Rasmussen D.D., Alexander L.L., Raskind M.A., Froehlich J.C. The alpha1-adrenergic receptor antagonist, prazosin, reduces alcohol drinking in alcohol-preferring (P) rats. Alcoholism, Clinical and Experimental Research 2009, 33(2):264-272. [Research Support, N.I.H., Extramural]. 10.1111/j.1530-0277.2008.00829.x.
225. Rasmussen D.D., Wilkinson C.W., Raskind M.A. Chronic daily ethanol and withdrawal: 6. Effects on rat sympathoadrenal activity during "abstinence". Alcohol 2006, 38(3):173-177. [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.]. 10.1016/j.alcohol.2006.06.007.
226. Reid M.S., Mickalian J.D., Delucchi K.L., Hall S.M., Berger S.P. An acute dose of nicotine enhances cue-induced cocaine craving. Drug and Alcohol Dependence 1998, 49(2):95-104. [Clinical Trial Randomized Controlled Trial Research Support, U.S. Gov't, P.H.S.].
227. Roberts D.C. Preclinical evidence for GABAB agonists as a pharmacotherapy for cocaine addiction. Physiology and Behavior 2005, 86(1-2):18-20. [Comparative Study Review]. 10.1016/j.physbeh.2005.06.017.
228. Roberts D.C., Brebner K. GABA modulation of cocaine self-administration. Annals of the New York Academy of Sciences 2000, 909:145-158. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review].
229. Roberts A.C., Robbins T.W., Weiskrantz L. The prefrontal cortex executive and cognitive functions 1998, Oxford University Press, Oxford.
230. Rothman R.B., Baumann M.H. Serotonin releasing agents. Neurochemical, therapeutic and adverse effects. Pharmacology, Biochemistry and Behavior 2002, 71(4):825-836. [Review].
231. Rothman R.B., Baumann M.H. Monoamine transporters and psychostimulant drugs. European Journal of Pharmacology 2003, 479(1-3):23-40. [Review].
232. Rothman R.B., Baumann M.H. Serotonergic drugs and valvular heart disease. Expert Opinion on Drug Safety 2009, 8(3):317-329. [Research Support, N.I.H., Intramural Review]. 10.1517/14740330902931524.
233. Rothman R.B., Blough B.E., Baumann M.H. Dual dopamine/serotonin releasers: Potential treatment agents for stimulant addiction. Experimental and Clinical Psychopharmacology 2008, 16(6):458-474. [Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Review]. 10.1037/a0014103.
234. Rothman R.B., Blough B.E., Woolverton W.L., Anderson K.G., Negus S.S., Mello N.K., et al. Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration. The Journal of Pharmacology and Experimental Therapeutics 2005, 313(3):1361-1369. [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.]. 10.1124/jpet.104.082503.
235. Rothman R.B., Partilla J.S., Dersch C.M., Carroll F.I., Rice K.C., Baumann M.H. Methamphetamine dependence: Medication development efforts based on the dual deficit model of stimulant addiction. Annals of the New York Academy of Sciences 2000, 914:71-81. [Comparative Study Review].
236. Rounsaville B.J., Anton S.F., Carroll K., Budde D., Prusoff B.A., Gawin F. Psychiatric diagnoses of treatment-seeking cocaine abusers. Archives of General Psychiatry 1991, 48(1):43-51. [Research Support, U.S. Gov't, P.H.S.].
237. Rush C.R., Stoops W.W. Agonist replacement therapy for cocaine dependence: A translational review. Future Medicinal Chemistry 2012, 4(2):245-265. [Research Support, N.I.H., Extramural Review]. 10.4155/fmc.11.184.
238. Saal D., Dong Y., Bonci A., Malenka R.C. Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons. Neuron 2003, 37(4):577-582. doi: S0896627303000217 [pii].
239. Sahakian B.J., Morris R.G., Evenden J.L., Heald A., Levy R., Philpot M., et al. A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson's disease. Brain 1988, 111(Pt. 3):695-718. [Comparative Study Research Support, Non-U.S. Gov't].
240. Saladin M.E., Gray K.M., Carpenter M.J., LaRowe S.D., DeSantis S.M., Upadhyaya H.P. Gender differences in craving and cue reactivity to smoking and negative affect/stress cues. The American Journal on Addictions 2012, 21(3):210-220. [Research Support, N.I.H., Extramural]. 10.1111/j.1521-0391.2012.00232.x.
241. Sallee F.R., McGough J., Wigal T., Donahue J., Lyne A., Biederman J. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: A placebo-controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry 2009, 48(2):155-165. [Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't]. 10.1097/CHI.0b013e318191769e.
242. Sanchez-Hervas E., Llorente del Pozo J.M. Relapse in cocaine addiction: A review. Adicciones 2012, 24(3):269-279. Review.
243. Sara S.J. The locus coeruleus and noradrenergic modulation of cognition. Nature Reviews Neuroscience 2009, 10(3):211-223. [Research Support, Non-U.S. Gov't Review]. 10.1038/nrn2573.
244. Sawaguchi T., Goldman-Rakic P.S. The role of D1-dopamine receptor in working memory: Local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. Journal of Neurophysiology 1994, 71(2):515-528.
245. Scahill L. Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness. CNS Drugs 2009, 23(Suppl. 1):43-49. [Review]. 10.2165/00023210-200923000-00006.
246. Scahill L., Aman M.G., McDougle C.J., Arnold L.E., McCracken J.T., Handen B., et al. Trial design challenges when combining medication and parent training in children with pervasive developmental disorders. Journal of Autism and Developmental Disorders 2009, 39(5):720-729. [Randomized Controlled Trial Research Support, N.I.H., Extramural]. 10.1007/s10803-008-0675-2.
247. Scahill L., Chappell P.B., Kim Y.S., Schultz R.T., Katsovich L., Shepherd E., et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. The American Journal of Psychiatry 2001, 158(7):1067-1074. [Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
248. Schneider U., Altmann A., Baumann M., Bernzen J., Bertz B., Bimber U., et al. Comorbid anxiety and affective disorder in alcohol-dependent patients seeking treatment: The first Multicentre Study in Germany. Alcohol and Alcoholism 2001, 36(3):219-223. [Multicenter Study].
249. Schroeder J.R., Schmittner J., Bleiberg J., Epstein D.H., Krantz M.J., Preston K.L. Hemodynamic and cognitive effects of lofexidine and methadone coadministration: A pilot study. Pharmacotherapy 2007, 27(8):1111-1119. [Clinical Trial, Phase I Research Support, N.I.H., Intramural]. 10.1592/phco.27.8.1111.
250. Schwartz T.L., Nihalani N. Tiagabine in anxiety disorders. Expert Opinion on Pharmacotherapy 2006, 7(14):1977-1987. [Review]. 10.1517/14656566.7.14.1977.
251. Seedat Y.K. Clonidine and guanfacine-Comparison of their effects on haemodynamics in hypertension. South African Medical Journal 1985, 67(14):557-559. [Comparative Study Review].
252. Sees K.L., Clark H.W. Substance abusers want to stop smoking!. Alcoholism, Clinical and Experimental Research 1991, 15:152.
253. Seo D., Jia Z., Lacadie C.M., Tsou K.A., Bergquist K., Sinha R. Sex differences in neural responses to stress and alcohol context cues. Human Brain Mapping 2011, 32(11):1998-2013. [Research Support, N.I.H., Extramural]. 10.1002/hbm.21165.
254. Shaham Y., Shalev U., Lu L., De Wit H., Stewart J. The reinstatement model of drug relapse: History, methodology and major findings. Psychopharmacology 2003, 168(1-2):3-20. [Review]. 10.1007/s00213-002-1224-x.
255. Shalev U., Grimm J.W., Shaham Y. Neurobiology of relapse to heroin and cocaine seeking: A review. Pharmacological Reviews 2002, 54(1):1-42. [Research Support, U.S. Gov't, P.H.S. Review].
256. Shang C.Y., Gau S.S. Improving visual memory, attention, and school function with atomoxetine in boys with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology 2012, 22(5):353-363. [Research Support, Non-U.S. Gov't]. 10.1089/cap.2011.0149.
257. Shields A.D., Wang Q., Winder D.G. Alpha2a-adrenergic receptors heterosynaptically regulate glutamatergic transmission in the bed nucleus of the stria terminalis. Neuroscience 2009, 163(1):339-351. [Research Support, N.I.H., Extramural]. 10.1016/j.neuroscience.2009.06.022.
258. Shorter D., Kosten T.R. Novel pharmacotherapeutic treatments for cocaine addiction. BMC Medicine 2011, 9(119). [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S. Review]. 10.1186/1741-7015-9-119.
259. Shorter D., Lindsay J.A., Kosten T.R. The alpha-1 adrenergic antagonist doxazosin for treatment of cocaine dependence: A pilot study. Drug and Alcohol Dependence 2013, 131(1-2):66-70. [Research Support, N.I.H., Extramural]. 10.1016/j.drugalcdep.2012.11.021.
260. Sica D.A. Centrally acting antihypertensive agents: An update. Journal of Clinical Hypertension (Greenwich, Conn.) 2007, 9(5):399-405. [Review].
261. Simpson T.L., Saxon A.J., Meredith C.W., Malte C.A., McBride B., Ferguson L.C., et al. A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence. Alcoholism, Clinical and Experimental Research 2009, 33(2):255-263. [Randomized Controlled Trial Research Support, Non-U.S. Gov't]. 10.1111/j.1530-0277.2008.00807.x.
262. Sinha R. How does stress increase risk of drug abuse and relapse?. Psychopharmacology 2001, 158(4):343-359. [Research Support, U.S. Gov't, P.H.S. Review]. 10.1007/s002130100917.
263. Sinha R. Chronic stress, drug use, and vulnerability to addiction. Annals of the New York Academy of Sciences 2008, 1141:105-130.
264. Sinha R., Fox H.C., Hong K.A., Bergquist K., Bhagwagar Z., Siedlarz K.M. Enhanced negative emotion and alcohol craving, and altered physiological responses following stress and cue exposure in alcohol dependent individuals. Neuropsychopharmacology 2009, 34(5):1198-1208. [Research Support, N.I.H., Extramural]. 10.1038/npp.2008.78.
265. Sinha R., Fox H.C., Hong K.I., Hansen J., Tuit K., Kreek M.J. Effects of adrenal sensitivity, stress- and cue-induced craving, and anxiety on subsequent alcohol relapse and treatment outcomes. Archives of General Psychiatry 2011, 68(9):942-952. [Research Support, N.I.H., Extramural]. 10.1001/archgenpsychiatry.2011.49.
266. Sinha R., Garcia M., Paliwal P., Kreek M.J., Rounsaville B.J. Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcomes. Archives of General Psychiatry 2006, 63(3):324-331. [Comparative Study Research Support, N.I.H., Extramural]. 10.1001/archpsyc.63.3.324.
267. Sinha R., Hong A.K., Seo D., Fox H.C., Bergquist K.L. Neural and endocrine predictions of alcohol relapse risk. Alcoholism, Clinical and Experimental Research 2010, 34(6):290A. Supplement.
268. Sinha R., Kimmerling A., Doebrick C., Kosten T.R. Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: Preliminary findings. Psychopharmacology 2007, 190(4):569-574. [Randomized Controlled Trial Research Support, N.I.H., Extramural]. 10.1007/s00213-006-0640-8.
269. Sinha R., Lacadie C., Skudlarski P., Fulbright R.K., Rounsaville B.J., Kosten T.R., et al. Neural activity associated with stress-induced cocaine craving: A functional magnetic resonance imaging study. Psychopharmacology 2005, 183(2):171-180. [Comparative Study Research Support, N.I.H., Extramural]. 10.1007/s00213-005-0147-8.
270. Sinha R., Shaham Y., Heilig M. Translational and reverse translational research on the role of stress in drug craving and relapse. Psychopharmacology 2011, 218(1):69-82. [Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Review]. 10.1007/s00213-011-2263-y.
271. Sinha R., Talih M., Malison R., Cooney N., Anderson G.M., Kreek M.J. Hypothalamic-pituitary-adrenal axis and sympatho-adreno-medullary responses during stress-induced and drug cue-induced cocaine craving states. Psychopharmacology 2003, 170(1):62-72. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. 10.1007/s00213-003-1525-8.
272. Smith R.J., Aston-Jones G. Noradrenergic transmission in the extended amygdala: Role in increased drug-seeking and relapse during protracted drug abstinence. Brain Structure and Function 2008, 213(1-2):43-61. [Review]. 10.1007/s00429-008-0191-3.
273. Smith R.J., Aston-Jones G. Alpha(2) adrenergic and imidazoline receptor agonists prevent cue-induced cocaine seeking. Biological Psychiatry 2011, 70(8):712-719. [Research Support, N.I.H., Extramural]. 10.1016/j.biopsych.2011.06.010.
274. Sofuoglu M. Cognitive enhancement as a pharmacotherapy target for stimulant addiction. Addiction 2010, 105(1):38-48. [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S. Review]. 10.1111/j.1360-0443.2009.02791.x.
275. Sofuoglu M., DeVito E.E., Waters A.J., Carroll K.M. Cognitive enhancement as a treatment for drug addictions. Neuropharmacology 2013, 64:452-463. [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S. Review]. 10.1016/j.neuropharm.2012.06.021.
276. Sommer B.R., Mitchell E.L., Wroolie T.E. Topiramate: Effects on cognition in patients with epilepsy, migraine headache and obesity. Therapeutic Advances in Neurological Disorders 2013, 6(4):211-227. 10.1177/1756285613481257.
277. Sorkin E.M., Heel R.C. Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs 1986, 31(4):301-336. [Review].
278. Steere J.C., Arnsten A.F. The alpha-2A noradrenergic receptor agonist guanfacine improves visual object discrimination reversal performance in aged rhesus monkeys. Behavioral Neuroscience 1997, 111(5):883-891.
279. Strang J.J., Bearn J., Gossop M. Lofexidine for opiate detoxification: Review of recent randomised and open controlled trials. The American Journal on Addictions 1999, 8(4):337-348.
280. Summers R.J., Jarrott B., Louis W.J. Comparison of [3H]clonidine and [3H]guanfacine binding to alpha 2 adrenoceptors in membranes from rat cerebral cortex. Neuroscience Letters 1981, 25(1):31-36. [Research Support, Non-U.S. Gov't].
281. Swartz B.E., McDonald C.R., Patel A., Torgersen D. The effects of guanfacine on working memory performance in patients with localization-related epilepsy and healthy controls. Clinical Neuropharmacology 2008, 31(5):251-260. [Comparative Study]. 10.1097/WNF.0b013e3181633461.
282. Taneja I., Haman K., Shelton R.C., Robertson D. A randomized, double-blind, crossover trial of modafinil on mood. Journal of Clinical Psychopharmacology 2007, 27(1):76-79. [Randomized Controlled Trial Research Support, N.I.H., Extramural]. 10.1097/jcp.0b013e31802eb7ea.
283. Taylor H.R., Freeman M.K., Cates M.E. Prazosin for treatment of nightmares related to posttraumatic stress disorder. American Journal of Health-System Pharmacy 2008, 65(8):716-722. [Review]. 10.2146/ajhp070124.
284. Taylor F.B., Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. Journal of Clinical Psychopharmacology 2001, 21(2):223-228.
285. Thanos P.K., Michaelides M., Benveniste H., Wang G.J., Volkow N.D. The effects of cocaine on regional brain glucose metabolism is attenuated in dopamine transporter knockout mice. Synapse 2008, 62(5):319-324. [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.]. 10.1002/syn.20503.
286. Thanos P.K., Taintor N.B., Rivera S.N., Umegaki H., Ikari H., Roth G., et al. DRD2 gene transfer into the nucleus accumbens core of the alcohol preferring and nonpreferring rats attenuates alcohol drinking. Alcoholism, Clinical and Experimental Research 2004, 28(5):720-728. [Comparative Study Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.].
287. Tice D.M., Bratslavsky E., Baumeister R.F. Emotional distress regulation takes precedence over impulse control: If you feel bad, do it!. Journal of Personality and Social Psychology 2001, 80(1):53-67. [Clinical Trial Randomized Controlled Trial Research Support, U.S. Gov't, P.H.S.].
288. Tzschentke T.M. Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Progress in Neurobiology 2001, 63(3):241-320.
289. Ungless M.A., Whistler J.L., Malenka R.C., Bonci A. Single cocaine exposure in vivo induces long-term potentiation in dopamine neurons. Nature 2001, 411(6837):583-587. [In Vitro Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. 10.1038/35079077.
290. van Zwieten P.A. The renaissance of centrally acting antihypertensive drugs. Journal of Hypertension. Supplement 1999, 17(3):S15-S21. [Review].
291. Verdejo-Garcia A., Perez-Garcia M. Ecological assessment of executive functions in substance dependent individuals. Drug and Alcohol Dependence 2007, 90(1):48-55. [Research Support, Non-U.S. Gov't]. 10.1016/j.drugalcdep.2007.02.010.
292. Verrico C.D., Haile C.N., Newton T.F., Kosten T.R., De La Garza R. Pharmacotherapeutics for substance-use disorders: A focus on dopaminergic medications. Expert Opinion on Investigational Drugs 2013, 22:1549-1568. 10.1517/13543784.2013.836488.
293. Viola T.W., Tractenberg S.G., Pezzi J.C., Kristensen C.H., Grassi-Oliveira R. Childhood physical neglect associated with executive functions impairments in crack cocaine-dependent women. Drug and Alcohol Dependence 2013, 132(1-2):271-276. 10.1016/j.drugalcdep.2013.02.014.
294. Vocci F., Ling W. Medications development: Successes and challenges. Pharmacology & Therapeutics 2005, 108(1):94-108. [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S. Review]. 10.1016/j.pharmthera.2005.06.010.
295. Volkow N.D., Fowler J.S., Wang G.J., Goldstein R.Z. Role of dopamine, the frontal cortex and memory circuits in drug addiction: Insight from imaging studies. Neurobiology of Learning and Memory 2002, 78(3):610-624. [Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.].
296. Volkow N.D., Fowler J.S., Wang G.J., Swanson J.M. Dopamine in drug abuse and addiction: Results from imaging studies and treatment implications. Molecular Psychiatry 2004, 9(6):557-569. [Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S. Review]. 10.1038/sj.mp.4001507.
297. Vranjkovic O., Hang S., Baker D.A., Mantsch J.R. Beta-adrenergic receptor mediation of stress-induced reinstatement of extinguished cocaine-induced conditioned place preference in mice: Roles for beta1 and beta2 adrenergic receptors. The Journal of Pharmacology and Experimental Therapeutics 2012, 342(2):541-551. [Research Support, N.I.H., Extramural]. 10.1124/jpet.112.193615.
298. Waldrop A.E., Back S.E., Verduin M.L., Brady K.T. Triggers for cocaine and alcohol use in the presence and absence of posttraumatic stress disorder. Addictive Behaviors 2007, 32(3):634-639. [Comparative Study Research Support, N.I.H., Extramural]. 10.1016/j.addbeh.2006.06.001.
299. Waldrop A.E., Price K.L., Desantis S.M., Simpson A.N., Back S.E., McRae A.L., et al. Community-dwelling cocaine-dependent men and women respond differently to social stressors versus cocaine cues. Psychoneuroendocrinology 2010, 35(6):798-806. [Comparative Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 10.1016/j.psyneuen.2009.11.005.
300. Wang M., Ji J.Z., Li B.M. The alpha(2A)-adrenergic agonist guanfacine improves visuomotor associative learning in monkeys. Neuropsychopharmacology 2004, 29(1):86-92. [Comparative Study Research Support, Non-U.S. Gov't]. 10.1038/sj.npp.1300278.
301. Wang M., Ramos B.P., Paspalas C.D., Shu Y., Simen A., Duque A., et al. Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell 2007, 129(2):397-410. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 10.1016/j.cell.2007.03.015.
302. Wang B., Shaham Y., Zitzman D., Azari S., Wise R.A., You Z.B. Cocaine experience establishes control of midbrain glutamate and dopamine by corticotropin-releasing factor: A role in stress-induced relapse to drug seeking. The Journal of Neuroscience 2005, 25(22):5389-5396. 10.1523/JNEUROSCI.0955-05.2005.
303. Washton A.M., Resnick R.B. The clinical use of clonidine in outpatient detoxification from opiates. Progress in Clinical and Biological Research 1981, 71:277-284. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
304. Williams N., Simpson A.N., Simpson K., Nahas Z. Relapse rates with long-term antidepressant drug therapy: A meta-analysis. Human Psychopharmacology 2009, 24(5):401-408. [Meta-Analysis Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 10.1002/hup.1033.
305. Wiseman E.J., McMillan D.E. Relationship of cessation of cocaine use to cigarette smoking in cocaine-dependent outpatients. The American Journal of Drug and Alcohol Abuse 1998, 24(4):617-625.
306. Witkiewitz K., Marlatt G.A. Emphasis on interpersonal factors in a dynamic model of relapse. The American Psychologist 2005, 60(4):341-342. [Comment]. 10.1037/0003-066X.60.4.341.
307. Wong Y.N., Simcoe D., Hartman L.N., Laughton W.B., King S.P., McCormick G.C., et al. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. Journal of Clinical Pharmacology 1999, 39(1):30-40. [Clinical Trial Randomized Controlled Trial].
308. Woodward J.J., Mansbach R., Carroll F.I., Balster R.L. Cocaethylene inhibits dopamine uptake and produces cocaine-like actions in drug discrimination studies. European Journal of Pharmacology 1991, 197(2-3):235-236. [Comparative Study Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
309. Yamada H., Bruijnzeel A.W. Stimulation of alpha2-adrenergic receptors in the central nucleus of the amygdala attenuates stress-induced reinstatement of nicotine seeking in rats. Neuropharmacology 2011, 60(2-3):303-311. [Comparative Study Research Support, N.I.H., Extramural]. 10.1016/j.neuropharm.2010.09.013.
310. Zahrt J., Taylor J.R., Mathew R.G., Arnsten A.F. Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. The Journal of Neuroscience 1997, 17(21):8528-8535. [Research Support, U.S. Gov't, P.H.S.].